https://www.selleckchem.com/pr....oducts/alexidine-dih
Treatment of metastatic germ cell cancer (GCC) is based on the International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic classification published in 1997. 5-year survival rates were reported to be 91%, 79%, and 48% for patients with good, intermediate and poor prognosis, respectively. However, treatment results may have improved over time due to cumulative experience, improved supportive care and modern-type chemotherapy. Patients with metastatic GCC who received cisplatin-based chemotherapy at two institu
Like
Comment
Share
